ArriVent BioPharma (AVBP) EBIT (2023 - 2026)

ArriVent BioPharma has disclosed EBIT across 4 years of filings, most recently posting -$46.1 million for Q1 2026.

• EBIT for Q1 2026 came in at -$46.1 million, up 30.94% year-over-year; the trailing twelve-month figure through Mar 2026 was -$156.9 million (down 11.73% YoY), and the FY2025 annual result was -$177.5 million, down 88.25% from the prior year.
• EBIT came in at -$46.1 million for Q1 2026 at ArriVent BioPharma, down from -$38.8 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$12.2 million in Q1 2023 to a low of -$66.8 million in Q1 2025.
• The 4-year median for EBIT is -$24.2 million (2024), against an average of -$30.2 million.
• Across the five-year window, EBIT sank 222.98% in 2025 and jumped 30.94% in 2026, its largest moves.
• ArriVent BioPharma's EBIT stood at -$23.1 million in 2023, then slipped by 2.54% to -$23.7 million in 2024, then slumped by 63.78% to -$38.8 million in 2025, then slipped by 18.77% to -$46.1 million in 2026.
• The last three EBIT figures came in at -$46.1 million (Q1 2026), -$38.8 million (Q4 2025), and -$38.3 million (Q3 2025), per Business Quant data.